# Trial to Evaluate Efficacy and Safety of Pembrolizumab and Gemcitabine in HER2-negative ABC

> **NCT03025880** · PHASE2 · COMPLETED · sponsor: **Spanish Breast Cancer Research Group** · enrollment: 36 (actual)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT03025880
- **Lead sponsor:** Spanish Breast Cancer Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-28
- **Primary completion:** 2019-06-03
- **Final completion:** 2021-07-22
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2023-04-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03025880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03025880, "Trial to Evaluate Efficacy and Safety of Pembrolizumab and Gemcitabine in HER2-negative ABC". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03025880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*